C225-ILs-dox

C225-ILs-dox is an investigational anti-EGFR immunoliposome loaded with doxorubicin, developed by the University Hospital Basel in Switzerland. It is a targeted nanoparticle delivery system constructed by conjugating the antigen-binding fragments (Fab') of the anti-EGFR monoclonal antibody cetuximab (C225) to the surface of pegylated liposomal doxorubicin (commercially known as Caelyx or Doxil). This drug is designed to selectively target and bind to the Epidermal Growth Factor Receptor (EGFR), which is frequently overexpressed in various solid tumors. Upon binding, the immunoliposome is internalized via receptor-mediated endocytosis, allowing for the intracellular release of doxorubicin. This targeted approach aims to enhance the therapeutic efficacy of doxorubicin within tumor tissues while significantly reducing systemic toxicities, particularly cardiotoxicity and skin reactions typically associated with EGFR inhibitors.

Other names

anti-EGFR immunoliposomes loaded with doxorubicindoxorubicin-loaded anti-EGFR-immunoliposomeanti-EGFR-ILs-dox